Molecular profiling and access to treatment for rare cancers in Europe

Abstract

Arcagen is a clinical study proposing a comprehensive analysis of molecular and clinical characteristics of rare adult solid cancers (11 domains: sarcomas, gynecology, uro-genital, GI, NET, head and neck, thoracic, skin and eyes, CNS and CUP) across Europe, utilizing the EORTC-SPECTA platform with the EURACAN ERN. This study enrolled 1235 advanced stage patients. 893 were evaluable for molecular profiling toward a potential access to personalized therapy.In the 11 different domains, 69.4% (620/893) of patients had actionable mutations, among whom 93 (15% of 620 patients with currently actionable alterations) received targeted- or immune (IO)-therapies. The median overall survival of the patient population without treatment adaptation, with switch to targeted therapy, or immunotherapy was 1.1, 3.3 years, and not reached, respectively.Across Europe, high prevalence and diversity of molecular alterations for rare solid tumors were observed as well as significant disparities regarding access to personalized medicine approaches. Molecular characterization of rare cancer types can be challenging, and this can limit application of personalized therapy. Here, the authors compile a large clinical cohort of rare adult solid cancers to find 69% harbour actionable mutations.

Hybrid quantum-classical attention for histopathology-based molecular profiling in data-limited cancers
Kahn Rhrissorrakrai, Aritra Bose, Aldo Guzman-Saenz +2
arXiv2 Oct 2026PreprintCC BY 4.0Full textGenetics & genomics Quantum physics & quantum informationarXiv
An ensemble framework for robust drug response prediction and large-scale sensitivity profiling across cancers
Yuanlong Feng, Shiling Zhou, Shengnan Luo +8
Communications Biology8 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textGeneral biologyCrossref
Access to Genetic Testing in Patients With Suspected Genetic Kidney Disease in Europe.
Margriet E Gosselink, Femke Buining, Jens König +10
Kidney international reports8 Sep 2026Peer-reviewedCC BYFull textGenetics & genomicsEurope PMC
Comparative profiling of MAIT cells across gastrointestinal cancers identifies conserved NK receptor dysregulation and HCC-specific defects in cytotoxicity and XBP1s signaling
Vanessa Proß, Annkathrin Helena Ruhm, Linda Marie Laura Thole +21
Frontiers in Immunology5 Oct 2026Peer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMC
Circulating tumor DNA in body fluids for molecular characterization of cancers beyond tissue and blood
Aditya Shreenivas, Sewanti Limaye, Massimo Cristofanilli +10
iScience14 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulation Genetics & genomicsCell PressCrossrefEurope PMC

Cite

BibTeX RIS

BibTeX

@article{morfouace2026molecular,
  title = {{Molecular profiling and access to treatment for rare cancers in Europe}},
  author = {M. Morfouace and F. Hoogstoel and J. Oliveira and N. Penel and S. Tejpar and I. Ray-Coquard and J. Peron and M. Pracht and B. Brasiuniene and A. Capela and C. Gennigens and L. Greillier and C. Even and R. Huang and T. Gorlia and G. Lombardi and M. Gamulin and L. Licitra and N. Girard and H. Klümpen and A. Idbaih and Wta van der Graaf and J. Blay},
  journal = {Nature Communications},
  year = {2026},
  month = jul,
  doi = {10.1038/s41467-026-75776-1},
  url = {https://hal.science/hal-05749328v1},
  note = {CC BY-NC-ND},
}

RIS

TY  - JOUR
TI  - Molecular profiling and access to treatment for rare cancers in Europe
AU  - M. Morfouace
AU  - F. Hoogstoel
AU  - J. Oliveira
AU  - N. Penel
AU  - S. Tejpar
AU  - I. Ray-Coquard
AU  - J. Peron
AU  - M. Pracht
AU  - B. Brasiuniene
AU  - A. Capela
AU  - C. Gennigens
AU  - L. Greillier
AU  - C. Even
AU  - R. Huang
AU  - T. Gorlia
AU  - G. Lombardi
AU  - M. Gamulin
AU  - L. Licitra
AU  - N. Girard
AU  - H. Klümpen
AU  - A. Idbaih
AU  - Wta van der Graaf
AU  - J. Blay
PY  - 2026
DA  - 2026/07/23
JO  - Nature Communications
DO  - 10.1038/s41467-026-75776-1
UR  - https://hal.science/hal-05749328v1
AB  - Arcagen is a clinical study proposing a comprehensive analysis of molecular and clinical characteristics of rare adult solid cancers (11 domains: sarcomas, gynecology, uro-genital, GI, NET, head and neck, thoracic, skin and eyes, CNS and CUP) across Europe, utilizing the EORTC-SPECTA platform with the EURACAN ERN. This study enrolled 1235 advanced stage patients. 893 were evaluable for molecular profiling toward a potential access to personalized therapy.In the 11 different domains, 69.4% (620/893) of patients had actionable mutations, among whom 93 (15% of 620 patients with currently actionable alterations) received targeted- or immune (IO)-therapies. The median overall survival of the patient population without treatment adaptation, with switch to targeted therapy, or immunotherapy was 1.1, 3.3 years, and not reached, respectively.Across Europe, high prevalence and diversity of molecular alterations for rare solid tumors were observed as well as significant disparities regarding access to personalized medicine approaches. Molecular characterization of rare cancer types can be challenging, and this can limit application of personalized therapy. Here, the authors compile a large clinical cohort of rare adult solid cancers to find 69% harbour actionable mutations.
SN  - 2041-1723
SN  - 2041-1723
ER  -

Abstract

Related

Cite